Skip to search formSkip to main contentSkip to account menu

AT 877

Known as: AT-877, AT877 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Isoquinolinesfasudil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage
SummaryThe initial dose-escalating clinical trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid… 
Review
2001
Review
2001
Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm.
Fasudil HCl (HA1077, AT877, Eril) was first introduced as a unique vasodilator and intracellular calcium antagonist. It dilated… 
1994
1994
Pretreatment of Transient Focal Cerebral Ischemia in Rats With the Calcium Antagonist AT877
Background and Purpose The efficacy of pretreatment with the recently developed intracellular calcium antagonist AT877 against… 
1993
1993
AT‐877, a Ca2+ antagonist, fails to reduce infarct size following rat middle‐cerebral artery occlusion
We investigated the effects of AT‐877, a Ca2+ antagonist, on rat middle‐cerebral artery occlusion. All rats had 6‐h ischemia, and… 
Review
1990
Review
1990
New pharmacological strategies in vascular diseases: a novel intracellular calcium antagonist, HA1077 (AT-877) and cerebral vasospasm.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)